Starpharma Holdings Ltd. | Mutual Funds
Mutual Funds that own Starpharma Holdings Ltd.
Fidelity Funds SICAV - Pacific Fund
20,797,524
5.61%
-728,484
0.81%
05/31/2018
Allan Gray Australia Equity Fund
13,052,254
3.52%
-5,107
1.08%
12/31/2017
Allianz Global Investors Fund - Oriental Income
7,421,197
2%
-287,700
2.15%
05/31/2018
Vanguard Total International Stock Index Fund
5,328,031
1.44%
0
0%
07/31/2018
Manulife Global Fund - Asian Small Cap Equity Fund
2,912,051
0.79%
2,912,051
0.94%
12/31/2017
Vanguard Australian Shares Index Fund
2,616,476
0.71%
205,643
0.03%
07/31/2018
Vanguard Developed Markets Index Fund
2,009,197
0.54%
0
0%
07/31/2018
Government Pension Fund - Global (The)
1,702,594
0.46%
196,385
0%
12/31/2017
Tiburon Funds Plc - Taipan Fund
1,643,796
0.44%
0
5.32%
07/31/2018
NEF - Azionario Pacifico
890,706
0.24%
15,240
0.83%
12/31/2017
| Address |
4-6 Southampton Crescent
Abbotsford Victoria (VIC) 3067
Australia
|
|
Employees
|
- |
| Website |
http://www.starpharma.com |
| Updated |
07/08/2019 |
| Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. |
